News

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Single healthcare-focused institutional investor $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full…

2 years ago

Longeveron® to Attend BIO International Convention 2024

MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular…

2 years ago

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet…

2 years ago

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…

2 years ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects…

2 years ago

Spectral AI to Participate in Benzinga’s “AI Unleashed: Exploring the Possibilities” Virtual Event

DALLAS, May 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

2 years ago

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762

Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May…

2 years ago

Q1 Interim Report January-March 2024

STOCKHOLM, SWEDEN / ACCESSWIRE / May 28, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) Press release: Stockholm, 28 May 2024. PMD…

2 years ago

Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease

Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's diseaseOne of Evotec's largest strategic drug…

2 years ago

IRLAB Presents at Redeye Growth Day 30 May

GOTHENBURG, SE / ACCESSWIRE / May 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 28, 2024 - IRLAB Therapeutics…

2 years ago